Literature DB >> 23275035

Treatment for diplopia in patients with myasthenia gravis.

Kyung-Ah Park1, Sei Yeul Oh.   

Abstract

BACKGROUND: The purpose of this study was to describe the treatment experiences and outcomes of patients with myasthenia gravis (MG) whose initial presenting symptom was diplopia
METHODS: A retrospective review was performed on a group of patients with MG whose initial presenting symptom was diplopia.
RESULTS: The mean age of onset was 45.5 ± 16.9 years, and the mean follow-up period was 45.4 ± 39.7 months. Exotropia with vertical heterotropia was the most common type of deviation. The mean horizontal deviation was 20.1 ± 17.9 prism diopters, and the mean vertical deviation was 14.8 ± 11.1 prism diopters. Limitation of eye movement was found in 20 patients (71.4 %) during the follow-up period. After conventional treatment for MG, six patients (21.4 %) showed a good response with resolution of diplopia. Four patients (14.3 %) showed a partial response to treatment. Eighteen patients (64.3 %) showed minimal or no response; among them, ten (35.7 %) had an angle of deviation of 15 prism diopters or more. Six patients underwent strabismus surgery. Four were symptom free, and satisfactorily aligned after surgical treatment. One patient had intermittent diplopia despite the small amount of deviation, and one patient experienced recurrence of exotropia with diplopia during the 10-year follow-up. In multivariable analysis, the only factor associated with the need for strabismus surgery was the initial angle of deviation (p = 0.016).
CONCLUSIONS: Patients with MG who have a larger angle of deviation at presentation tend to require strabismus surgery after stabilization of the disease. Strabismus surgery is one treatment option for patients with MG who have a large angle of deviation and respond poorly to conventional treatment.

Entities:  

Mesh:

Year:  2012        PMID: 23275035     DOI: 10.1007/s00417-012-2227-x

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  15 in total

1.  MYASTHENIA GRAVIS: A REVIEW OF THE DISEASE AND A DESCRIPTION OF LID TWITCH AS A CHARACTERISTIC SIGN.

Authors:  D G COGAN
Journal:  Arch Ophthalmol       Date:  1965-08

2.  Strabismus surgery in the management of diplopia caused by myasthenia gravis.

Authors:  O C Morris; J O'Day
Journal:  Br J Ophthalmol       Date:  2004-06       Impact factor: 4.638

Review 3.  Ocular aspects of myasthenia gravis.

Authors:  J J Barton; M Fouladvand
Journal:  Semin Neurol       Date:  2000       Impact factor: 3.420

4.  Active management in patients with ocular manifestations of myasthenia gravis.

Authors:  C R Bentley; E Dawson; J P Lee
Journal:  Eye (Lond)       Date:  2001-02       Impact factor: 3.775

Review 5.  Myasthenia gravis. A clinical and basic science review.

Authors:  M E Seybold
Journal:  JAMA       Date:  1983-11-11       Impact factor: 56.272

Review 6.  Ocular myasthenia: diagnosis, treatment, and pathogenesis.

Authors:  Linda L Kusner; Araya Puwanant; Henry J Kaminski
Journal:  Neurologist       Date:  2006-09       Impact factor: 1.398

7.  Extraocular muscle surgery in myasthenia gravis.

Authors:  J F Acheson; J S Elston; J P Lee; P Fells
Journal:  Br J Ophthalmol       Date:  1991-04       Impact factor: 4.638

Review 8.  Ocular myasthenia: a protean disorder.

Authors:  D A Weinberg; R L Lesser; T L Vollmer
Journal:  Surv Ophthalmol       Date:  1994 Nov-Dec       Impact factor: 6.048

9.  Childhood ocular myasthenia gravis.

Authors:  Jong-Hyun Kim; Jeong-Min Hwang; Yong Seung Hwang; Ki Joong Kim; Jonghee Chae
Journal:  Ophthalmology       Date:  2003-07       Impact factor: 12.079

10.  Postoperative outcomes in children with intermittent exotropia from a population-based cohort.

Authors:  Noha S Ekdawi; Kevin J Nusz; Nancy N Diehl; Brian G Mohney
Journal:  J AAPOS       Date:  2008-10-10       Impact factor: 1.220

View more
  2 in total

1.  Strabismus surgery and long-term visual outcomes in patients with preadolescent onset ocular myasthenia gravis.

Authors:  Jinu Han; So Young Han; Sueng-Han Han; Jong Bok Lee
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-11-16       Impact factor: 3.117

2.  Local use of dexamethasone in the treatment of ocular myasthenia gravis.

Authors:  Minghua Shi; Yingjia Ye; Junping Zhou; Aijiao Qin; Jing Cheng; Hongxing Ren
Journal:  BMC Ophthalmol       Date:  2020-10-28       Impact factor: 2.209

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.